Phathom Pharmaceuticals, Inc. (PHAT)
NASDAQ: PHAT · Real-Time Price · USD
5.94
+0.20 (3.48%)
At close: Oct 26, 2026, 4:00 PM EDT
6.00
+0.06 (1.02%)
Pre-market: Oct 27, 2026, 4:16 AM EDT

Phathom Pharmaceuticals Stock Forecast

Stock Price Forecast

According to 12 analysts polled by S&P Global, Phathom Pharmaceuticals stock has a consensus rating of "Buy" and an average price target of $19.64. The average 1-year stock price forecast is 230.64% higher than the current stock price, while the lowest is $10 (+68.35%) and the highest is $29 (+388.22%).

Price Target: $19.64 (+230.64%)
Analyst Consensus: Buy

Price Target

Chart
TargetLowAverageMedianHigh
Price$10$19.64$21$29
Change+68.35%+230.64%+253.54%+388.22%

Analyst Ratings

The average analyst rating for Phathom Pharmaceuticals stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.

Recommendation Trends

Chart
RatingMay '26Jun '26Jul '26Aug '26Sep '26Oct '26
Strong Buy778888
Buy222222
Hold111122
Sell000000
Strong Sell000000
Total101011111212

Latest Forecasts

AnalystFirmRatingRatingActionPrice TargetUpsideDate
Cantor Fitzgerald
Cantor Fitzgerald
Buy
Maintains
n/a
BuyMaintainsn/an/aOct 23, 2026
Craig-Hallum
Craig-Hallum
Buy
Maintains
$20 → $15
BuyMaintains$20 → $15+152.53%Oct 21, 2026
H.C. Wainwright
H.C. Wainwright
Buy
Maintains
$26
BuyMaintains$26+337.71%Sep 21, 2026
Leerink Partners
Leerink Partners
Hold
Initiates
$10
HoldInitiates$10+68.35%Sep 9, 2026
Barclays
Barclays
Buy
Maintains
$14
BuyMaintains$14+135.69%Aug 17, 2026
More Analyst Ratings

Financial Forecast

Revenue This Year
315.24M
from 175.11M
Increased by 80.03%
Revenue Next Year
489.37M
from 315.24M
Increased by 55.24%
EPS This Year
-0.04
from -2.06
EPS Next Year
0.96
from -0.04
Fiscal YearFY 2021FY 2022FY 2023FY 2024FY 2025FY 2026
Period EndingDec 31, 2021Dec 31, 2022Dec 31, 2023Dec 31, 2024Dec 31, 2025Dec 31, 2026
Revenue
--682.00K55.25M175.11M315.24M
Revenue Growth
---8,001.47%216.93%80.03%
Gross Profit
--515.00K47.28M152.51M252.04M
Gross Margin
--75.51%85.57%87.09%79.95%
Operating Income
-135.08M-172.44M-167.31M-277.47M-159.99M-1.73M
Net Income
-143.88M-197.72M-201.59M-334.33M-221.25M-65.72M
EPS
-----2.06-0.04
Free Cash Flow
-----167.00M-54.65M
No. Analysts
-----10
EPS and Forward PE are based on non-GAAP adjusted numbers.

Revenue Forecast

Revenue202620272028
High323.1M
Avg315.2M
Low310.0M

Revenue Growth

Revenue Growth202620272028
High
84.5%
Avg
80.0%
Low
77.0%

EPS Forecast

EPS202620272028
High0.04
Avg-0.04
Low-0.16

EPS Growth

EPS Growth202620272028
High-
Avg-
Low-